共 50 条
- [1] Ixekizumab provides improvements through 52 weeks in physical function, quality of life, and work productivity in biologic diseasemodifying antirheumatic drug (bDMARD) naive patients with active psoriatic arthritis (PsA)JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 4 - 4Gottlieb, A. B.Husni, M. E.Shuler, C. L.Burge, R.Lin, C. -Y.Lee, C. H.Gladman, D. D.
- [2] Ixekizumab Provides Improvements through 52 Weeks in Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic ArthritisARTHRITIS & RHEUMATOLOGY, 2016, 68Gottlieb, Alice B.Husni, M. ElaineShuler, Catherine L.Burge, Russel T.Lin, Chen-YenLee, Chin H.Gladman, D.
- [3] IXEKIZUMAB PROVIDES IMPROVEMENTS THROUGH 52 WEEKS IN PHYSICAL FUNCTION, QUALITY OF LIFE, AND WORK PRODUCTIVITY IN BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITISANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 345 - 345Gottlieb, A. B.Husni, M. E.Shuler, C. L.Burge, R.Lin, C. -Y.Lee, C. H.Gladman, D. D.
- [4] Ixekizumab improves physical function, quality of life, and work productivity in biologic disease-modifying antirheumatic drug-naive patients with active psoriatic arthritisJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB257 - AB257Gottlieb, Alice B.Mease, PhilipCuchacovich, RaquelShuler, Catherine L.Lin, Chen-YenBurge, Russel T.Samanta, SuvajitLee, ChinGladman, Dafna D.
- [5] Ixekizumab Improves Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic ArthritisARTHRITIS & RHEUMATOLOGY, 2015, 67Gottlieb, Alice B.Mease, Philip J.Cuchacovich, Raquel S.Shuler, Catherine L.Lin, Chen-YenBurge, Russel T.Samanta, SuvajitLee, Chin H.Gladman, Dafna D.
- [6] Ixekizumab Provides Sustained Improvement up to 52 Weeks of Disease Activity As Assessed By Composite Measure Scores in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic ArthritisARTHRITIS & RHEUMATOLOGY, 2016, 68Coates, Laura C.Husni, M. ElaineShuler, Catherine L.Carlier, HildeLin, Chen-YenMou, JianiLee, Chin H.Mease, Philip J.
- [7] IXEKIZUMAB PROVIDES SUSTAINED IMPROVEMENT UP TO 52 WEEKS OF DISEASE ACTIVITY AS ASSESSED BY COMPOSITE MEASURE SCORES IN BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG (BDMARD)-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITISANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 349 - 350Coates, L. C.Husni, M. E.Shuler, C. L.Carlier, H.Lin, C-YMou, J.Lee, C. H.Mease, P. J.
- [8] BIMEKIZUMAB MAINTAINED EFFICACY RESPONSES THROUGH 52 WEEKS IN BIOLOGIC DISEASEMODIFYING ANTIRHEUMATIC DRUG-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS WHO WERE RESPONDERS AT WEEK 16: RESULTS FROM BE OPTIMAL, A PHASE 3, ACTIVE-REFERENCE STUDYANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1130 - 1131Tillett, W.Merola, J. F.Tanaka, Y.Favalli, E. G.Mcgonagle, D.Walsh, J. A.Thaci, D.Ink, B.Bajracharya, R.Taieb, V.Ritchlin, C. T.
- [9] Sustained Improvements in Physical Function, Quality of Life, and Work Productivity after Ixekizumab Therapy in Patients with Active Psoriatic Arthritis: 3-Year ResultsARTHRITIS & RHEUMATOLOGY, 2018, 70Fleischmann, RoyChandran, VinodLespessailles, EricBirt, JulieBenichou, OlivierErickson, JanelleShuler, Catherine
- [10] EFFICACY AND SAFETY OF IXEKIZUMAB AT WEEK 52 IN BIOLOGIC NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (SPIRIT-P1)RHEUMATOLOGY, 2018, 57Lespessailles, EricKirkham, BruceNebro, Antonio FernandezBlanco, RicardoStrehblow, ChristophInciarte-Mundo, JosePorsdal, VibekeGarcia, MiriamKurzawa, MonikaSapin, ChristopheGeusens, PietGoupille, PhilippeTahir, Hasan